帕尼培南-倍他米隆治疗恶性血液病合并感染患者的疗效分析  

Analysis on curative effect of panipenem-betamipron in treatment of malignant hematopathy patients

作　　者：罗伟[1] 李占全[1] 崔森[1] 冀林华[1] 耿惠[1] 马晓静[1] 

机构地区：[1]青海大学附属医院血液科,青海西宁810001

出　　处：《现代预防医学》2012年第21期5796-5797,共2页Modern Preventive Medicine

摘　　要：目的分析帕尼培南-倍他米隆治疗恶性血液病合并感染患者的疗效。方法选取某院血液科2007～2012年间收治的恶性血液病伴感染118例患者作为研究对象,随机均分为观察组与对照组。对照组患者常规使用亚胺培南-西司他丁,观察组患者使用帕尼培南-倍他米隆,比较两组患者的治疗效果及不良反应发生情况。结果观察组患者的治疗效果明显优于对照组(P﹤0.05),接受治疗后的不良反应出现率明显小于对照组(P﹤0.05),两者差异有统计学意义。结论使用帕尼培南-倍他米隆用于恶性血液病合并感染患者的治疗,可以显著提高其临床效果,减少不良反应发生,值得广泛应用。OBJECTIVE To analyze of panipenem-betamipron for treatment of malignant hematological disease complicated with infection in patients.METHODS 118 cases with hematologic malignancies complicated with infection in Department of Hematology in 2007-2012 were slelected and randomly divided into observation group and control group.Patients in the control group used panipenem-cilastatin,the patients in the observation group used panipenem-betamipron,compared the treatment effect and occurrence of adverse reaction in two groups.RESULTS The therapeutic effect in the observation group was significantly better than of control group（P﹤0.05）,the adverse reaction rate in the observation group after treatment was significantly lower than that of control group（P﹤0.05）,both with a significant differences.CONCLUSION The use of panipenem-betamipron for malignant hematologic disease complicated with infection in patients can significantly improve the clinical effect,reduce the adverse reaction,and is worth to be widely used.

关 键 词：帕尼培南-倍他米隆 恶性血液病 感染 

分 类 号：R969.4[医药卫生—药理学]